Why Kymera Therapeutics Stock Popped This Week
It's getting quite the head start on an important clinical trial.
Overview
This week was an eventful one for Kymera Therapeutics (NASDAQ: KYMR). The clinical-stage biotech announced the early completion of enrollment in an important clinical trial. It also earned a clutch of analyst price target raises. These developments were tempered by news of an insider stock sale.
Regardless, by Friday's market close, Kymera had risen by almost 30% over the five trading days, according to data compiled by S&P Global Market Intelligence.
Details
Kymera, which specializes in medicines that use a process called targeted protein degradation (TPD), announced Thursday morning that it completed enrollment in a global Phase 2b trial of its leading drug candidate. This is KT-621, which will be tested in a trial to assess its efficacy in treating severe atopic dermatitis, a chronic skin condition.
Source
Originally published at www.fool.com.
Related Articles
- Trump admin allows Anthropic to release Mythos AI model to some companies, government agencies: Reports
- Why Harmony Gold Mining Stock Plummeted by Almost 12% This Week
- After Issuing Its First Stock Split in 2020, Tesla Took Just 2 Years to Issue Its Second Split. Could a Third Stock Split Come in 2026?